NeurAxis (NRXS) to Post Earnings on Tuesday

NeurAxis (NASDAQ:NRXS) is anticipated to announce its results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.32) per share and revenue of $2.00 million for the quarter.

NeurAxis Stock Up 2.3%

NASDAQ:NRXS opened at $7.09 on Friday. The company has a fifty day moving average of $6.92 and a 200 day moving average of $6.62. NeurAxis has a 52 week low of $2.20 and a 52 week high of $9.33. The firm has a market capitalization of $88.46 million, a P/E ratio of -3.85 and a beta of 1.49.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NRXS. State Street Corp bought a new stake in NeurAxis in the fourth quarter valued at $139,000. Rosalind Advisors Inc. bought a new position in NeurAxis in the 4th quarter worth $1,299,000. Geode Capital Management LLC lifted its position in shares of NeurAxis by 48.8% in the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock worth $343,000 after purchasing an additional 24,817 shares during the period. Citadel Advisors LLC lifted its position in shares of NeurAxis by 39.6% in the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock worth $110,000 after purchasing an additional 10,103 shares during the period. Finally, Manatuck Hill Partners LLC bought a new stake in shares of NeurAxis during the 2nd quarter valued at about $122,000. Hedge funds and other institutional investors own 11.77% of the company’s stock.

NeurAxis Company Profile

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.